CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 130 enrolled
Drug / intervention
tasisulamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00383292
NCT00383292Phase 2Completed
CompareCT.gov

A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle as Second-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Eli Lilly and Company·interventional·Posted Oct 3, 2006·Updated Jun 6, 2018

In Brief

A Phase 2 clinical trial evaluating tasisulam for Metastatic Melanoma. Completed, enrolled 130 participants across 13 sites in 2 countries.

Detailed Summary

The primary purpose of this study is to determine the objective response rate (complete and partial response) for participants who receive tasisulam after one prior systemic treatment for unresectable or metastatic melanoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Melanoma
CountriesAustralia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 3, 2006
Enrollment StartNov 1, 2006
Primary CompletionSep 1, 2011
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 19.7 years ago

Interventions

tasisulamdrug

Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.